Home › Research › Topics › donepezil
donepezil
271 studies tagged donepezil, dated 1981-01-01 to 2026-10-14. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
271 studies carry this tag.
Date range
1981 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 15
- Neurology 11
- Journal of the American Geriatrics Society 9
- Research Square 8
- medRxiv 8
138 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
We aimed to summarise current evidence on different antidiabetic drugs to delay cognitive impairment, including mild cognitive impairment, dementia, Alzheimer's disease (AD) and vascular dementia, among subjects with type 2 diabetes mellitus (T2DM).
-
Quality pharmacological treatment can improve survival in many types of cancer.
-
Alzheimer's disease (AD) treatment includes both non-pharmacological and pharmacological approaches.
-
The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer's disease and schizophrenia.
-
We identified 1,994 records in five different databases; after exclusion of duplicates, title and abstract screening, and full-text retrieval, 122 studies were finally included.
-
Vascular dementia (VD) is a neurocognitive disorder whose precise definition is still up for debate.
-
Compared with placebo, the amino acid mixture did not improve NPI-12, MMSE, TMT-A and B or CDR scores.
-
We identified 107,931 beneficiaries with ≥1 month as an AL resident and 323,766 beneficiaries with ≥1 month as a LSNH resident with dementia, including 1,923,867 person-months and 4,984,405 person-months, respectively.
-
Anti-dementia medications are widely prescribed to patients with Alzheimer's dementia (AD) in South Korea.
-
We screened 18,884 papers and included 135 studies.
-
Overall, 1343 patients with MMSE scores were identified for internal validation and 285 [21.22%] took the drug recommended.
-
Patients treated with bryostatin pre-specified at Mini-Mental State Examination scores 10-14, without memantine, showed baseline balance, complete safety, and SIB improvements at 13 weeks with multiple imputation analysis: Study #203 = 4.1 SIB points above baseline (p = 0.005), and Study #202 = 4.2 SIB points above baseline (p = 0.016).
-
When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event.
-
Almost half of patients of nursing home residents experience one fall per year.
-
From May 13, 2015, to July 22, 2020, 185 participants with Down syndrome were assessed for eligibility and 160 (86%) were randomly assigned either memantine (n=81) or placebo (n=79).
-
Following reports of bleeding upon Ginkgo intake, we assessed whether Ginkgo extract EGb 761® affects coagulation or platelet function or increases the risk of bleeding.
-
The study included 524,975 older adults with dementia who were incident users of ChEIs (donepezil 80.72%, rivastigmine 16.41%, galantamine 2.87%).
-
Between Jan 26, 2017, and March 6, 2020, 204 participants were recruited and randomised.
-
Between Aug 28, 2013, and Dec 21, 2015, we enrolled 3494 participants (3061 at high risk and 433 at low risk).
-
73/100
The study included 47,059 older adults with dementia who were incident users of AChEIs.
-
Group 3 showed less decrease in the SIB score at 12 and 24 weeks compared with group 1 (P < 0.05).
-
The study cohort consisted of 178,441 older adults with dementia who were new users of ChEIs.
-
No significant difference in ADAS-Cog13, CDR Sum of Boxes (CDR-SOB), or FAQ scores were found between treatment groups at 3 and 6 months.
-
There were no significant differences in age, sex, or education between AChEIs alone and combination groups.
-
55/100
Gabapentin was the most common medication and was associated with 33.0% of polypharmacy-days.
-
The sample was mostly female (65%), White (76%), and 74 years old on average.
-
Lewy body dementia (LBD) is asynucleinopathy that results in clinical manifestation of motor and neuropsychiatric symptoms.
-
All patients completed 100%of study visits and infusions.
-
39/100
It is important to have a wide perspective to provide appropriate medical care for the oldest-old individuals.
-
Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder often neuropathologically associated with the accumulation of abnormally hyperphosphorylated tau, for which there is currently no disease-modifying treatment.
-
46/100
A total of 13 case reports were found (10 for donepezil, 2 for galantamine and 1 for rivastigmine) with rate corrected QT interval (QTc) prolongation.
-
The use of anticholinergic medications among patients with OAB was associated with an increased risk of new-onset dementia compared to beta-3 agonist users.
-
39/100
Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia.
-
41/100
Consensus diagnostic criteria for MCI are available, making early recognition and accurate classification of MCI subtypes possible.
-
43/100
Among persons diagnosed with ADRD or related symptoms, 33.3% used an approved drug over the study period.
-
39/100
Dementia can be seen as a clinical syndrome featuring a decline in cognitive and psychological abilities that can cause disability.
-
Compared with low-dose donepezil, galantamine use was associated with a lower risk of mortality (adjusted hazard ratio: 0.84, 95% confidence interval: 0.60-1.18), cardiovascular serious adverse events (adjusted hazard ratio: 0.78, 95% confidence interval: 0.62-0.98), and entry into a residential care facility (adjusted hazard ratio: 0.72, 95% confidence interval: 0.59-0.89).
-
The average age in our 2 groups was 81.1 years, and 61.4% of our population was female.
-
In our final study sample (N = 21,558), significant difference in survival among index AD medication groups were observed with donepezil being associated with better survival than memantine, and oral and transdermal forms of rivastigmine for both ITT and as-treated analysis.
-
This study investigated the association of statin use with sepsis risk in patients with dementia.
-
The total sample consisted of 33 clinically diagnosed AD patients taking galantamine 8 mg/d for 6 months.
-
The foundation of current Alzheimer's disease (AD) treatment involves pharmacological and nonpharmacological management and care planning predicated on patient-centered psychoeducation, shared goal-setting, and decision-making forged by a strong triadic relationship between clinician and the patient-caregiver dyad.
-
The same daily ACB score was associated with a different degree of risk, depending on the ACB ratings of the individual drugs comprising the score.
-
Nursing homes underreport their antipsychotic prescribing levels, on average, by 1 percentage point per quarter relative to Medicare Part D claims (0.013, 95% confidence interval (CI), 0.012-0.015; p<.001).
-
The safety profile was similar for 20 μg treatment and placebo patients.
-
Overall 47 trials, 38 animal and 9 human, were isolated for inclusion in this review.
-
Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in China.
-
Currently, five pharmacotherapeutic options are available to treat Alzheimer's disease: memantine; the three cholinesterase inhibitors donepezil, galantamine, and rivastigmine; and combination treatments with memantine and one cholinesterase inhibitor.
-
Alzheimer's disease (AD) results in progressively worsening cognitive decline, leading to loss of functional ability, behavior/mood disturbances, institutionalization, and death.
-
The French Minister of Health published a decree on May 29th of 2018 removing the drugs used to fight against symptoms due to Alzheimer's disease (donepezil, rivastigmine, galantamine, memantine) from the list of available reimbursed drugs.
From across this tag
8 of the 271 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- The Latest Advances in the Diagnosis and Treatment of Dementia
- Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study
- Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis
- Effects of pioglitazone on the incidence of dementia in patients with diabetes
- A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule
- Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis
- Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis
- Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial